Prevention of critical telomere shortening by oestradiol in human normal hepatic cultured cells and carbon tetrachloride induced rat liver fibrosis

Gut

Volumn 53, Issue 7, 2004, Pages 1001-1009

  Sato, R ^a   Maesawa, C ^a   Fujisawa, K ^a   Wada, K ^a   Oikawa, K ^a   Takikawa, Y ^a   Suzuki, K ^a   Oikawa, H ^a   Ishikawa, K ^b   Masuda, T ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

^b IWATE PREFECTURAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CARBON TETRACHLORIDE; ESTRADIOL; MESSENGER RNA; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL LINE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EXPOSURE; ENZYME ACTIVITY; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; INCIDENCE; LIVER CELL; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SENESCENCE; TELOMERASE REVERSE TRANSCRIPTASE GENE; TELOMERE; TRANSACTIVATION; UPREGULATION;

ANIMALS; BETA-GALACTOSIDASE; CARBON TETRACHLORIDE; CELL AGING; CELL LINE; DNA-BINDING PROTEINS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION; HEPATOCYTES; HUMANS; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; RATS; RATS, INBRED F344; RECEPTORS, ESTROGEN; RNA, MESSENGER; TELOMERASE; TELOMERE;

EID: 3042662816     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.027516     Document Type: Article

References (54)

1. Wiemann SU, Satyanarayana A, Tsahuridu M, et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J 2002;16:935-42.
2. Rudolph KL, Depinho RA. Telomeres and telomerase in experimetol liver cirrhosis. In: Arias IM, Boyer JL, Chisari FV, et al. The liver: biology and pathobiology. Philadelphia: Lippincott Williams and Wilkins, 2001:1000-10.
3. Kitada T, Seki S, Kawakito N, et al. Telomere shortening in chronic liver diseases. Biochem Biophys Res Commun 1995;211:33-9.
4. Miura N, Horikawa I, Nishimoto A, et al. Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis. Cancer Genet Cytogenet 1997;93:56-62.
5. Urabe Y, Nouso K, Higashi T, et al. Telomere length in human liver diseases. Liver 1996;16:293-7.
6. Aikata H, Takaishi H, Kawakami Y, et al. Telomere reduction in human liver tissues wild age and chronic inflammation. Exp Cell Res 2000;256:578-82.
7. Arthur MJ. Fibrosis and altered matrix degradation. Digestion 1998;59:376-80.
8. Friedman SL. Cellular networks in hepatic fibrosis. Digestion 1998;59:368-71.
9. Schuppan D, Cho JJ, Jia JD, et al. Interplay of matrix and myofibroblasts during hepatic fibrogenesis. Curr Topic Pathol 1999;93:205-18.
10. Martinez-Hernandez A, Amenta PS. The hepatic extracellular matrix. II. Ontogenesis, regeneration and cirrhosis. Virchows Arch A Pathol Anat Histopathol 1993;423:77-84.
11. Fausta N, Mead JE, Gruppuso PA, et al. Effects of TGF-betas in the liver: cell proliferation and fibrogenesis. Ciba Found Symp 1991;157:165-74.
12. Milani S, Herbst H, Schuppan D, et al. Transforming growth factors beta 1 and beta 2 are differentially expressed in fibrotic liver disease. Am J Pathol 1991;139:1221-9.
13. Roulot D, Sevcsik AM, Coste T, et al. Role of transforming growth factor beta type II receptor in hepatic fibrosis: studies of human chronic hepatitis C and experimental fibrosis in rats. Hepatology 1999;29:1730-8.
14. Bedossa P, Peltier E, Terris B, et al. Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology 1995;21:760-6.
15. Yasuda M, Shimizu I, Shiba M, et al. Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats. Hepatology 1999;29:719-27.
16. Lee KS, Buck M, Houglum K, et al. Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest 1995;96:2461-8.
17. Shimizu I, Mizobuchi Y, Yasuda M, et al. Inhibitory effect of oestradiol on activation of rat hepatic stellate cells in vivo and in vitro. Gut 1999;44:127-36.
18. Rudolph KL, Chang S, Millard M, et al. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science 2000;287:1253-8.
19. Williams EJ, Iredale JP. Liver cirrhosis. Postgrad Med J 1998;74:193-202.
20. Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993;328:1828-35.
21. Alcalado R, Arthur MJ, Iredale JP. Pathogenesis of liver fibrosis. Clin Sci (Lond) 1997;92:103-12.
22. Xu JW, Gong J, Chang XM, et al. Estrogen reduces CCL4-induced liver fibrosis in rats. World J Gastroenterol 2002;8:883-7.
23. Meyne J, Ratliff RL, Moyzis RK. Conservation of the human telomere sequence (TTAGGG)n among vertebrates. Proc Natl Acad Sci U S A 1989;86:7049-53.
24. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965;37:614-36.
25. Chin L, Artandi SE, Shen Q, et al. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell 1999;97:527-38.
26. Kyo S, Takakura M, Kanaya T, et al. Estrogen activates telomerase. Cancer Res 1999;59:5917-21.
27. Kyo S, Takakura M, Kohama T, et al. Telomerase activity in human endometrium. Cancer Res 1997;57:610-14.
28. Bednarek AK, Chu Y, Aldaz CM. Constitutive telomerase activity in cells with tissue-renewing potential from estrogen-regulated rat tissues. Oncogene 1998;16:381-5.
29. Williams CD, Boggess JF, LaMarque LR, et al. A prospective, randomized study of endometrial telomerase during the menstrual cycle. J Clin Endocrinol Metab 2001;86:3912-17.
30. Tanaka M, Kyo S, Takakura M, et al. Expression of telomerase activity in human endometrium is localized to epithelial glandular cells and regulated in a menstrual phase-dependent manner correlated with cell proliferation. Am J Pathol 1998;153:1985-91.
31. Meeker AK, Sommerfeld HJ, Coffey DS. Telomerase is activated in the prostate and seminal vesicles of the castrated rat. Endocrinology 1996;137:5743-6.
32. Maesawa C, Inabo T, Sato H, et al. A rapid biosensor chip assay far measuring of telomerase activity using surface plasmon resonance. Nucleic Acids Res 2003;31:E4-4.
33. Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995;92:9363-7.
34. de Lange T, DePinho RA. Unlimited mileage from telomerase? Science 1999;283:947-9.
35. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-15.
36. Taylor RS, Ramirez RD, Ogoshi M, et al. Detection of telomerase activity in malignant and nonmalignant skin conditions. J Invest Dermatol 1996;106:759-65.
37. Hiyama K, Hirai Y, Kyoizumi S, et al. Activation of telomerase in human lymphocytes and hematopaietic progenitor cells. J Immunol 1995;155:3711-15.
38. Cherif H, Tarry JL, Ozanne SE, et al. Ageing and telomeres: a study into organ- and gender-specific telomere shortening. Nucleic Acids Res 2003;31:1576-83.
39. Coviello-McLaughlin GM, Prowse KR. Telomere length regulation during postnatal development and ageing in Mus spretus. Nucleic Acids Res 1997;25:3051-8.
40. Melk A, Ramassar V, Helms LM, et al. Telomere shortening in kidneys with age. J Am Soc Nephrol 2000;11:444-53.
41. Bissell DM. Sex and hepatic fibrosis. Hepatology 1999;29:988-9.
42. Zaman SN, Melia WM, Johnson RD, et al. Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients. Lancet 1985;1:1357-60.
43. Villa E, Boldini GM, Pasquinelli C, et al. Risk factors for hepatocellular carcinoma in Italy. Male sex, hepatitis B virus, non-A non-B infection, and alcohol. Cancer 1988;62:611-15.
44. Tanaka K, Sakai H, Hashizume M, et al. Serum testosterone:estradiol ratio and the development of hepatocellular carcinoma among male cirrhotic patients. Cancer Res 2000;60:5106-10.
45. Yu MW, Chen CJ. Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res 1993;53:790-4.
46. Porter LE, Elm MS, Van Thiel DH, et al. Characterization and quantitotion of human hepatic estrogen receptor. Gastroenterology 1983;84:704-12.
47. Rassini GP, Baldini GM, Villa E, et al. Characterization of estrogen receptor from human liver. Gastroenterology 1989;96:1102-9.
48. Dai WJ, Jiang HC. Advances in gene therapy of liver cirrhosis: a review. World J Gastroenterol 2001;7:1-8.
49. Berger A. Cirrhosis may be amenable to telomerase treatment. BMJ 2000;320:536A.
50. Hagmann M. Biomedicine. New genetic tricks to rejuvenate ailing livers. Science 2000;287:1185-7.
51. Schnabl B, Choi YH, Olsen JC, et al. Immortal activated human hepatic stellate cells generated by ectopic telomerase expression. Lab Invest 2002;82:323-33.
52. Schnabl B, Purbeck CA, Choi YH, et al. Replicative senescence of activated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibrogenic phenotype. Hepatology 2003;37:653-64.
53. De Maria N, Manno M, Villa E. Sex hormones and liver cancer. Mol Cell Endocrinol 2002;193:59-63.
54. Yager JD Jr, Yager R. Oral contraceptive steroids as promoters of hepatocarcinogenesis in female Sprague-Dawley rats. Cancer Res 1980;40:3680-5.